Henry S. Sacks, PhD, MD
Icahn School of Medicine at Mount Sinai
Thomas C. Chalmers Clinical Trials Unit
1 Gustave L. Levy Place
New York, New York 10029
(212) 241-7856
Henry.Sacks@mssm.edu
Education
Williams College
Williamstown, MA
Albany Medical College
Albany, New York
BA with Honors (Chemistry)
Ph.D (Microbiology)
M.D.
1962
1971
1975
Postdoctoral Research and Training
Postdoctoral Trainee in Biostatistics
Stanford University Medical Center
Stanford, CA
1970-1972
Interdisciplinary Fellow
Department of Pathology (Neuropathology)
Albert Einstein College of Medicine
Bronx, New York
1972-1973
Intern and Resident in Medicine
University of Connecticut Health Center
Farmington, CT
1975-1977
Fellow in Infectious Diseases
University of Connecticut Health Center
Farmington, CT
1977-1979
Licensure and Certification
Licensed to practice medicine
Connecticut
New York - 137468
1976-1979
1979-
Diplomate
National Board of Medical Examiners
American Board of Internal Medicine
Infectious Diseases
Geriatric Medicine
1976
1978
1980
2011-2021
1
Hospital Appointments
Mount Sinai Hospital, New York, NY
Clinical Assistant Physician (Inf. Diseases)
Assistant Attending Physician
1979-1982
1982-1987
1987-93
1993-
Associate Attending Physician
Attending Physician
North General Hospital, New York, NY
Consultant in Infectious Diseases
1981- 90
Jewish Home and Hospital for the Aged, New York
Consultant in Infectious Diseases
l983-90
Academic Appointments
University of Connecticut School of Medicine
Farmington, CT
Instructor in Medicine
1978-1979
Mount Sinai School of Medicine of
The City University of New York, NY
Instructor in Medicine and Biomathematical Sciences
1979-1982
Assistant Professor of Medicine and Biomathematical Sciences
1982-1987
Associate Professor of Medicine and Biomathematical Sciences
1987-93
Director, Clinical Trials Unit
1986-
Associate Professor of Community Medicine
Professor of Community Medicine, Medicine
and Biomathematical Sciences
Professor of Pediatrics
Professor, Cancer Center
Professor, Geriatrics and Palliative Care
1992-1993
1993199419992005-
Honors and Awards
National Institutes of Health
Post-doctoral Traineeship
1970-1972
New York Regents Fellowship for
Graduate Study
1967-1970
New York Regents Medical Scholarship
1962
Committee of 1000 Faculty Achievement
Award in Clinical Sciences
1992
NIH/NCCAM Special Emphasis Panel (Study section)
2002-2010
Chair
2004
NIH/NCCAM KO7 Leadership Award in Complementary and Alternative Medicine
2001-2006
2
Professional Memberships
American College of Physicians (Fellow)
Infectious Disease Society of America (Fellow)
Society for Clinical Trials 1982-90
Program Committee (1984-1986)
Editorial Boards
Online Journal of Current Clinical Trials (Editor)
Mount Sinai Journal of Medicine
Lancet Infectious Diseases (Editorial consultant)
1994-97
1985-2005
2000-2009
Mount Sinai Teaching Responsibilities:
General Medicine- Teaching attending
Infectious disease service attending
Community Medicine I- Seminar Group Leader
Pharmacology (antibiotics) lecturer and small group leader
Course co-director- Clinical Research and Program Evaluation
Course director- CLR0006 Spectrum of Methods in Clinical Research
Course co-director- CLR0016 Spectrum of Methods in Clinical Research
Course co-director- MPH624 Comparative Effectiveness Research
1979-2000
1979-2000
1979-2012
1989-2010
2000-2009
201020102009-
Administrative Responsibilities
Director - Thomas C. Chalmers Clinical Trials Unit
1987Principal Investigator - Adult AIDS Clinical Trials Unit
1987-2000
Principal Investigator - Pediatric AIDS Clinical Trials Unit
1989-1997
Program Director - Student Summer Fellowship Program
1980-2000
Co-director, Fogarty AIDS International Training Program
2000Co-director, Clinical Research Curriculum Award (K30)
1999-2009
Associate director, World Trade Center Medical Monitoring and Treatment
Program Data and Coordinating Center
2006-2010
Committees:
Institutional Review Board
Academic Council
Steering Committee
Executive Faculty
Clinical Research Center Advisory Board
MD Admissions Committee
Community Medicine Promotions Committee Chair
MD-PhD Admissions Committee
19811985-92
1985-90
1985-89
1995-2000
2002-2013
2003-2007
2007-
3
BIBLIOGRAPHY
Henry S. Sacks, Ph.D. M.D.
February, 2013
Articles in Peer Reviewed Journals
l. Sacks HS, Covert SV. Clostridium botulinum type E toxin: Effect of pH and method of purification
on molecular weight. Appl Microbiol 1974;28:374-382.
2. Brostoff SW, Sacks HS, DalCanto M, Johnson AB, Raine CS, Wisniewsky H. The P-2 protein of
bovine myelin: Isolation and some chemical and immunological properties. J Neurochem
1974;23:1037-1043.
3. Brostoff S, Sacks HS, DiPaola C. The P-2 protein of bovine root myelin: Partial chemical
characterization. J Neurochem 1975;24:289-294.
4. Sacks HS, Lyons RW, Lahiri B. Adult respiratory distress syndrome in Rocky Mountain spotted
fever. Am Rev Resp Disease 1981;123:547-549.
5. Baum M, Anish D, Chalmers TC, Sacks HS, Smith H, Fagerstrom R. A survey of clinical trials of
antibiotic prophylaxis in colon surgery: Evidence against further use of no-treatment controls. N Engl J
Med 1981;305:795-799.
6. Sacks HS, Chalmers TC, Smith H. Randomized vs. historical controls for clinical trials. Am J Med
1982;72:233-240.
7. Kirschner E, Chalmers TC, Popper H, Gerber MA, Stenger RJ, Goldberg JD, Sacks HS. Observer
error in biopsy interpretations and outcome in chronic hepatitis. Mount Sinai J Med 1982;49: 472-474.
8. Moskowitz G, Sacks HS, Chalmers TC. Impact of randomized control trials on the treatment of
alcohol withdrawal. Adv Alcohol Substance Abuse 1982;2:101-112.
9. Moskowitz G, Chalmers TC, Sacks HS, Fagerstrom R, Smith H. Deficiencies of clinical trials of
alcohol withdrawal. Alcoholism: Clinical and Exp Research 1983;7:42-46.
10. Singer J, Sacks HS, Lucente FE, Chalmers TC. Physician attitudes toward clinical applications of
computer data base systems. JAMA 1983;249:1610-1614.
11. Sacks HS, Chalmers TC, Smith H. Sensitivity and specificity of clinical trials: Randomized
vs. historical controls. Arch Int Med 1983;143:753-756.
12. Caroscio JT, Kochwa S, Sacks HS, Cohen JA, Yahr M. Quantitative CSF IgG measurements in
multiple sclerosis and other neurological diseases: An update. Arch Neurol 1983;40:409-413.
13. Smith H, Chan SS, Reitman D, Chalmers TC, Sacks HS. A paired comparison method for evaluating
physician excellence. Medical Care. 1984;22:412-417.
14. Messer J, Reitman D, Sacks HS, Chalmers TC, Smith H. Association of adrenocorticosteroid therapy
and peptic ulcer. N Engl J Med 1983;309:21-24.
15. Chalmers TC, Celano P, Sacks HS, Smith H Jr. Treatment assignment bias in controlled clinical
trials. N Engl J Med 1983;309:1358-1361.
16. Wolke A, Kapelman B, Sacks HS, Schaffner F. Malignancy in primary biliary cirrhosis: High
incidence of breast cancer in affected women. Am J Med. 1984;76:1075-1078.
4
17. Weinstein RS, Oshins J, Sacks HS. Tuberculosis infection in Mount Sinai medical students l974-82.
Mount Sinai J Med 1984;51:283-286.
18. Mathur-Wagh U, Enlow RW, Spigland I, Winchester RJ, Sacks HS, Rorat E, Yancovitz S, Klein MJ,
William DC, Mildvan D. Longitudinal study of persistent generalized lymphadenopathy in homosexual
men: relation to acquired immunodeficiency syndrome. Lancet 1984;1:1033-1038.
19. Sacks HS, Rose DN, Chalmers TC. Should the risk of AIDS deter hepatitis B vaccination? A
decision analysis. JAMA 1984;252:3375-3377.
20. Wiesel J, Rose DN, Silver AL, Sacks HS, Bernstein RH. Lumbar puncture in asymptomatic late
syphilis: an analysis of the benefits and risks. Arch Int Med 1985;145:465-468.
21. Sacks HS, Chalmers TC, Berk AA, Reitman D. Should mild hypertension be treated? An attempted
meta-analysis of the clinical trials. Mount Sinai J Med 1985;52:265-270.
22. Sacks HS. in Wolf S, Lewis NJ, (eds.). Clinical Trials in Chronic Neuromuscular Diseases:
Proceedings of a Colloquium at Totts Gap Institute, Bangor, PA. Muscle and Nerve 1985;8:451-92.
23. Sacks HS. Meningococcal pneumonia and empyema. Am J Med 1986;80:290-291.
24. Ghows M, Rosen M, Sacks HS, et al. Transcutaneous oxygen monitoring during bronchoscopy.
Chest 1986; 89:543-544.
25. Bhaskar R, Reitman D, Sacks HS, Smith H, Chalmers TC. Loss of patients in clinical trials that
measure long-term survival following Myocardial Infarction. Controlled Clin Trials 1986; 7:134-148.
26. Meyers BR, Srulevitch EW, Sacks HS, et al. Pharmacokinetics of mezlocillin in patients with hepatic
disease. J Antimicrobial Chemotherapy 1986; 18:709-713.
27. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized
controlled trials. N Engl J Med 1987; 316:450-455.
28. Niland-Weiss J, Azen SP, Odom-Maryon T, Lui F, Hagerty C and The Transfusion Safety Study
Group (incl. Sacks HS). A Microcomputer-based distributed data management system for a large
cooperative study of transfusion associated acquired immunodeficiency syndrome. Computers and
Biomedical Research 1987;20:225-243.
29. Dickersin K, Chan SS, Chalmers TC, Sacks HS, Smith H. Publication bias in randomized control
trials. Controlled Clin Trials 1987;8:343-353.
30. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical
trials as a scientific discipline. I. Control of bias and comparison with large cooperative trials. Statistics
in Medicine 1987;6:315-325.
31. Chalmers TC, Berrier J, Sacks HS, Levin H, Reitman D, Nagalingam R. Meta-analysis of clinical
trials as a scientific discipline. II. Replicate variability and comparison of studies. Statistics in Medicine
1987;6:733-744.
32. Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomised controlled trials of nicotine
chewing gum. Lancet 1987;2:27-30.
33. Boissel JP, Sacks HS, Leizorovicz A, et al. Meta-analysis of clinical trials: Summary of an
international conference. Eur J Clin Pharmacol 1988;34:535-538.
5
34. Sacks HS, Ancona-Berk VA, Berrier J, Nagalingam R. Dipyridamole in the treatment of angina
pectoris: a meta-analysis. Clin Pharmacol & Therapeut 1988;6:610-615. (Reprinted in Thrombosis
Research 1990;Suppl XII:35-42).
35. Sze PC, Reitman D, Pincus M, Sacks HS, Chalmers TC. Anti- platelet agents in the secondary
prevention of stroke: A meta-analysis of the randomized control trials. Stroke 1988;19:436-42.
36. Cooper LS, Chalmers TC, McCally M, Berrier J, and Sacks HS. Magnetic Resonance Imaging: The
poor quality of early evaluations. JAMA 1988;259:3277-3280.
37. Chalmers TC, Berrier J, Hewitt P, Berlin J, Reitman D, Nagalingam R, Sacks HS. Meta-analysis of
randomized control trials as a method of estimating rare complications of non-steroidal anti-inflammatory
drug therapy. Aliment Pharmacol Therap (Suppl 1) 1988;2:9-26.
38. Sperling RS, Sacks HS, Mayer L, Berkowitz RL. Umbilical cord blood serosurvey for Human
Immunodeficiency Virus in parturient women in a voluntary hospital in New York City. Obstetrics &
Gynecology 1989;73:179-181.
39. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining
event rates from clinical trials. Statistics in Medicine 1989;8:141-151.
40. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control
trials of progestational agents in pregnancy. British J OBS GYN 1989;96:265-274.
41. Edwards VM, Mosley JW, and the Transfusion Safety Study Group (incl. Sacks HS).
Reproducibility in quality control of protein (Western) immunoblot assay for antibodies to human
immunodeficiency virus. Am J Clin Pathol 1989;91:75-78.
42. Fletcher MA, Azen SP, Adelsberg B, Gjerset G, Hassett J, et al and the Transfusion Safety Study
Group (incl. Sacks HS). Immunophenotyping in a multicenter study: The transfusion safety study
experience. Clin Immunol Immunopathol 1989;52:38-47.
43. Operskalski EA, Schiff ER, Kleinman SH, Busch M, et al and the Transfusion Safety Study Group
(incl. Sacks HS). Epidemiologic background of blood donors with antibody to human T-cell
lymphotropic virus. Transfusion 1989;29:746-748.
44. Kleinman SH, Niland JC, Azen SP, Operskalski EA, et al and the Transfusion Safety Study Group
(incl. Sacks HS). Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors
prior to screening. Transfusion 1989;29:572-580.
45. Chalmers TC, Hewitt P, Reitman D, Sacks HS. Selection and evaluation of empirical research in
technology assessment. Int J Technol Assess Health Care 1989;5:521-536.
46. Behrman R, Meyers BR, Mendelson MH, Sacks HS, Hirschman SZ. Central nervous system
infections in the elderly. Arch Int Med 1989;149:1596-1599.
47. Boissel JP, Blanchard J, Panak E, Peyrieux JC, Sacks HS. Considerations for the meta-analysis of
randomized clinical trials: Summary of a panel discussion. Controlled Clin Trials 1989;10:254-281.
48. Strain JJ, Fahs M, Fulop G, Sacks HS. AIDS: Epidemiology and Treatment Issues. Mount Sinai
Journal of Medicine 1989;56:233-37.
49. Lang DJ, Kovacs A, Zaia JA, Doelkin G, Niland JC, Aledort L, et al, and the Transfusion Safety
Study Group (incl. Sacks HS). Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus
infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations.
J of Acquired Immune Defic Syndr 1989;2:540-549.
6
50. Operskalski EA, Schiff ER, Kleinman SH, Busch M, Taylor PE, Parks WP, Lee H, Tomasulo PA,
Donegan E, Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group (incl.
Sacks HS). Epidemiologic background of blood donors with antibody to human T-cell lymphotropic
virus. Transfusion 1989;29:746-748.
51. Sacks HS, Rose D. Zidovudine prophylaxis for needlestick exposure to human immunodeficiency
virus: A decision analysis. J Gen Int Med 1990;5:132-137.
52. Volberding PA, Lagakos SS, Koch MA, et al and the AIDS Clinical Trials Group (incl. Sacks HS).
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with
fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-949.
53. Martin J, Sacks HS. Do HIV infected children in foster care have access to clinical trials of new
treatments? AIDS & Public Policy Journal 1990;5:3-8.
54. Sacks HS, Chalmers TC, Blum AL, Berrier J, Pagano D. Endoscopic hemostasis: An effective
therapy for bleeding peptic ulcers. JAMA 1990;264:494-499.
55. Sacks HS, Chalmers TC, Blum AL, Berrier J, Pagano D. Hemostase endoscopique: Un traitement
efficace des ulceres peptiques hemorragiques. Supplement gastro-enterologie du JAMA -1991;
16(222):303-312.
56. Donegan E, Busch MP, Galleshaw JA, Shaw GM, Mosley JW, and the Transfusion Safety Study
Group (incl. Sacks HS). Transfusion of blood components from a donor with human T-Lymphotropic
virus type II (HTLV-II) infection. Ann Int Med 1990;113:555-556.
57. Fischl MA, Parker CB, Petinelli C, et al., and the AIDS Clinical Trials Group (incl. Sacks HS). A
randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired
immunodeficiency syndrome. N Engl J Med 1990;323:1009-1014.
58. Fischl M, Richman DD, Hansen et al and the AIDS Clinical Trials Group (incl. Sacks HS). The
safety and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic HIV
infection. Ann Int Med 1990;112:727-737.
59. Parker JW, Adelsberg B, Azen SP, Boone D, Fletcher MA, Gjerset GF, Hassett J, et al, and the
Transfusion Safety Study Group (incl. Sacks HS). Leukocyte immunophenotyping by flow cytometry in
a multisite study: Standardization, quality control, and normal values in the transfusion safety study. Clin
Immunol & Immunopath 1990;55:187-220.
60. Busch MP, Taylor PE, Lenes BA, Kleinman SH, Stuart M, et al, and the Transfusion Safety Study
Group (incl. Sacks HS). Screening of selected male blood donors for p24 antigen of human
immunodeficiency virus type 1. N Engl J Med 1990;323:1308-12.
61. Donegan E, Stuart M, Niland JC, Sacks HS, and the Transfusion Safety Study Group. Infection with
Human Immunodeficiency Virus type 1 among recipients of antibody positive blood donations. Ann Int
Med 1990;113:733-739.
62. Miller K, Donegan E, Curran P, Shelley TJ and the Transfusion Safety Study Group (incl. Sacks
HS). Effects of counselling on knowledge about HIV-1 among transfusion recipients and their partners.
AIDS Care 1990;2:155-162.
63. Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset
GF, Koerper MA, Lewis BH, Pegelow CH, and the Transfusion Safety Study Group (incl. Sacks HS).
Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Vox
Sang 1990;59:129-135.
7
64. Jacobson JM, Worner TM, Sacks HS, Lieber CS: Human immunodeficiency virus and hepatitis B
virus infections in alcoholics. Prog Clin Biol Res 1990;325:67.
65. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D,
Abrams D, Wilber J, Winger E, Sacks HS, Hendricksen C, Moss A. Surrogate markers for survival in
patients with AIDS and ARC treated with zidovudine. Br Med J. 1991;302:73-78.
66. Strain JJ, Lyons JS, Hammer JS, Fahs M, Lebovits A, Sacks HS, et al. Cost offset from a psychiatric
C/L intervention with elderly hip fracture patients. Am J Psychiatry 1991;148:1044-49.
67. Mildvan D, Buzas J, Armstrong D, Antoniskis D, Sacks HS, Rhame FS, Mosbach EH, Pettinelli C.
An open label dose-ranging trial of AL721 in patients with persistent generalized lymphadenopathy and
AIDS-related complex. J Acquir Immun Defic Syndr 1991;4:945-951.
68. Lusher JM, Operskalski EA, Aledort LM, Hilgartner M, Dietrich SL, Gjerset GF, Donegan E,
Mosley JW, and the Transfusion Safety Study Group (incl. Sacks HS). Transmission of human
immunodeficiency virus injection to sexual and household contacts of persons with congenital
hematologic disorders. Pediatrics 1991;88(2):242-243.
69. Parks WP, Lenes BA, Tomasulo PA, Schiff ER, Parks ES, Shaw GM, Lee H, Yan HQ, Lai S,
Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group (incl. Sacks HS).
Human T-cell lymphotropic virus infection among blood donors in South Florida. J Acquir Immun Defic
Syndr 1991;4:89-96.
70. Fletcher MA, Gjerset GF, Hassett J, Donegan E, Parker JW, Mosley JW, and the Transfusion Safety
Study Group (incl. Sacks HS). Lymphocyte immunophenotypes among anti-HTLV-I/II-positive blood
donors and recipients. J Acquir Immun Defic Syndr 1991;4:628-632.
71. Merigan T.C., Amato D.A., Balsley J., et al, and the NHF-ACTG 036 study Group (incl. Sacks HS).
Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection
in asymptomatic patients with hemophilia. Blood 1991;78(4):900-906.
72. SOCA Research Group and the AIDS Clinical Trials Group (incl. Sacks HS). Mortality in patients
with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for
cytomegalovirus retinitis. N Engl J Med 1992;326:213-220.
73. Jacobson J, Worner T, Sacks HS, Lieber CS. HIV and HBV infection in alcoholics. J Studies in
Alcohol 1992;53:76-79.
74. Fahs MC, Fulop G, Strain J, Sacks HS, Muller C, Cleary PD, Schmeidler J, Turner B. The inpatient
AIDS unit: An empirical investigation of access, economic, and outcome issues. Am J Pub Health
1992;82:576-578.
75. Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS
Clinical Trials Group (ACTG) (incl. Sacks HS). Studies of ocular complications of AIDS foscarnetganciclovir cytomegalovirus retinitis trial: 1, Rationale, design, and methods. Controlled Clin Trials
1992;13: 22-39.
76. Halpern M, Szabo S, Hochberg E, Hammer GS, Lin J, Gurtman AC, Sacks HS, Shapiro RS,
Hirschman SZ. Renal aspergilloma: an unusual cause of infection in a patient with the acquired
immunodeficiency syndrome. Am J Med 1992;92:437-440.
77. Kahn JO, Lagakos SW, Richman DD, Cross A, Petinelli C, Liou SH, Brown M, Volberding PA,
Crumpacker CS, Beall G, Sacks HS, Merigan TC, Beltangady M, Smaldone L, Dolin R, and the NIAID
AIDS Clinical Trials Group. A controlled trial comparing continued zidovudine with didanosine in
8
human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
78. Ellenberg SS, Cooper E, Eigo J, Finkelstein DM, Hoth DF, Nusinoff-Lehrman S, Sacks HS.
Studying Treatments for AIDS: New Challenges for Clinical Trials - A Panel Discussion at the 1990
Annual Meeting of the Society for Clinical Trials. Controlled Clinical Trials 1992;13:272-292.
79. Cleary PD, Fahs MC, McMullen W, Fulop G, Strain J, Sacks HS, Muller C, Foley M, Stein E. Using
patient reports to assess hospital treatment of persons with AIDS: a pilot study. AIDS Care 1992;4:325332.
80. Donegan E, Pell P, Lee H, Shaw GM, Mosley JW, and the Transfusion Safety Study Group (incl.
Sacks HS). Transmission of human T-cell lymphotropic virus type I by blood components from a donor
lacking anti- p24: a case report. Transfusion 1992;32:68-71.
81. Aledort LM, Hilgartner MW, Pike MC, Dietrich SL, Gjerset GF, Koerper MA, Lian EYC, Lusher
JM, Mosley JW, and the Transfusion Safety Study Group (incl. Sacks HS). Variability in serial CD4
counts and relation to progression of HIV 1 infection to AIDS in hemophiliac patients. Br Med J.
1992;304:212-6.
82. Rose DN, Schechter CB, Sacks HS. Preventive medicine for HIV-infected patients: An analysis of
isoniazid prophylaxis for tuberculin reactors and for anergic patients. J Gen Int Med 1992;7:589-594.
83. Busch MP, Henrad DR, Hewlett IK, Mehaffey WF, Epstein JS, Allain J-P, Lee T-H, Mosley JW and
the Transfusion Safety Study Group.(incl. Sacks HS). Poor sensitivity, specificity, and reproducibility of
detection of HIV-1 DNA in serum by polymerase chain reaction. J Acquir Immun Defic Syndr
1992;5:872-877.
84. Transfusion Safety Study Group (incl. Sacks HS). Effect of age on human immunodeficiency virus
type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders.
Blood 1992:80:831-840.
85. Cheung TW, Matta R, Neibart E, Hammer G, Chusid ED, Sacks HS, Szabo S, Rose D. Intramuscular
pentamidine for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency
virus infection. Clinical Infectious Diseases 1993;16:22-25.
86. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected
patients: A policy analysis. The American Journal of Medicine 1993;94:160-168.
87. Sidtis JJ, Gatsonis C, Price RW et al and the AIDS Clinical Trials Group (incl. Sacks HS).
Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. American
Neurological Association 1993;33:343-349.
88. Hilgartner MW, Buckley JD, Operskalski EA, Pike MC, Mosley JW, and the Transfusion Safety
Study Group (incl. Sacks HS). Purity of factor VIII concentrates and serial CD4 counts. The Lancet
1993:341:1373-74.
89. Villari P, Spino C, Chalmers T, Lau J, Sacks HS, Cesarean section to reduce perinatal transmission
of human immunodeficiency virus: potential benefits and costs. Online Journal of Controlled Clinical
Trials 1993:Document 74.
90. Sacks HS. Treatment of early or asymptomatic HIV infection: Where are we and where do we go
from here? Online Journal Controlled Clinical Trials 1993:Document 93.
91. Kornbluth AA, Salomon P, Sacks HS, Mitty R, Janowitz HD. A meta-analysis of the effectiveness
of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993;16:215-8.
9
92. Sepkowitz AK, Telzak EE, Recalde S, Armstrong D, and the New York City Area Tuberculosis
Working Group (incl. Sacks HS). Tuberculosis susceptibility trends in New York City, 1987 to 1991.
Clinical Infectious Disease 1994;18:755-9.
93. Sattler FR, Frame P, Davis R, Nichols L, Shelton B, Akil B, Baughman R, Hughlett C, Weiss W,
Boyley CT, van der Horst C, Black J, Powderly W, Steigbigel RT, Leedom JM, Masur I, Feinberg J, and
the AIDS Clinical Trails Group 029/031 Research Team (incl. Sacks HS). Trimetrexate with leucovorin
versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii in patients
with AIDS: A Prospective, controlled multicenter investigation of the AIDS clinical trials group. J Inf
Diseases 1994;170:165-72.
94. Insua JT, Sacks HS, Lau TS, Pagano D, Reitman D, Lau J, Chalmers TC. Drug treatment of
hypertension in the elderly: A Meta-analysis. Ann Int Med 1994;121:355-362. (Cited as one of the most
significant papers of the year by ACP Journal Club and Lancet (1995;346(Suppl):7)
95. Studies of Ocular Complications of AIDS Research Group and the AIDS Clinical Trials Group (incl.
Sacks HS). Foscarnet-ganciclovir cytomegalovirus retinitis trial: 4.Visual outcomes. Ophthalmology
1994:101;1250-61.
96. Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, Van Dyke R, Bey M, Shearer
W, Jacovson RL, Jimenez E, O'Neil E, Bazin B, Delfraissy JF, Culnane M, Coombs R, Eikins M, and the
Pediatric AIDS Clinical Group (incl. Sacks HS). Reduction of maternal-infant transmission of human
immnodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
97. Spector SA, Gelber RD, McFrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM,
Livingston RA, Connor EM, and the Pediatric AIDS Clinical Trials Group (incl. Sacks HS). A
controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in
children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med
1994;331:1181-87.
98. Montgomery AB, Feigal DW, Sattler F, Mason GR, Catanzaro A, Edison R, Markowitz N, Johnson
E, Ogawa S, Rovzar M, Udem SA, Eden E, Hyslop N, Cheung TW,Kessler,H, Mildvan D, Giron JA,
Ettinger N, Crumpacker C, Frame P, Steigbigel N, van der Horst C, Hirsch M, Lederman MM, Hewitt
RG, Fallat R, Farber HW, Sacks HS, Eisman SA, Luce,JM, Boylan T, Adams M, Feinberg J, Hopewell
PC. Aerosol pentamidine versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired
immune deficiency syndrome. Am J Respir Crit Care Med 1995;151:1068-74.
99. Murray HW, Squires KE, Weiss W, Sledz S, Sacks HS, Hassett J, Cross A, Anderson RE, Dunkle
LM. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. The J.
Inf Diseases 1995;171(Suppl 2):S123-30.
100 Petersen EA, Ramirez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, Peterson DM,
Cross A, Anderson RE, Dunkle LM. Dose-related activity of stavudine in patients infected with the
human immunodeficiency virus.The J. Inf Diseases 1995;171 (Suppl 2):S131-9.
101. Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, Sacks HS. A Metaanalysis of early versus deferred zidovudine in HIV-infected patients without an AIDS-defining illness.
Ann Intern Med. 1995;122:856-866. (Abstracted in ACP Journal Club (Nov-Dec 1995).
102. SOCA Research Groups and AIDS Clinical Trials Group (incl. Sacks HS). Morbidity and toxic
effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial.
Arch Intern Med. 1995;155:65-74.
103. Volberding PA, Grimes JM, Lagakos SA, Stein DS, Spector SA, Fischl M, Collier AC, Phair J,
Hirsch MS, Hardy WD, Balfour HH, Reichman R, and the AIDS Clinical Trials Group (incl. Sacks HS).
Immediate versus deferred zidovudine in asymptomatic HIV-infected subjects with CD4 cell counts of
10
500 per microliter or greater. N Engl J Med 1995; 333:401-407.
104. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical
Trials Group (incl. Sacks HS). Antiviral effects of foscarnet and ganciclovir therapy on human
immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. The J. Inf
Diseases 1995;172:613-21.
105. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine
in elderly persons: A Meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527.
(Included in the Cochrane Collaboration Database of Abstracts of Reviews of Effectiveness as
"Probably the most influential systematic review available in this field.")
106. Leport G, Chene G, Morlat P, Luft B, Rousseau F, Pueyo S, Hafner R, Miro J, Aubertin J, Salamon
R, Vilde J-L, and The AIDS Clinical Trials Group (incl. Sacks HS). Pyrimethamine for primary
prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: A
double-blind, randomized trial. The J. Inf Diseases 1996;173:91-7.
107. Ioannidis JPA, Cappelleri JC, Skolnick PR, Lau J, Sacks HS. A meta-analysis of the relative
efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Int Med. 1996;156:177-188.
108. SOCA Research Groups and the AIDS Clinical Trials Group (incl. Sacks HS). Combination
foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis
in patients with AIDS. Arch Ophthalmol 1996;114: 23-33.
109. Ioannidis JPA, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load
measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS 1996;10:255262.
110. Mildvan D, Bassiakos Y, Zucker ML, Hyslop Jr. N, Krown SE, Sacks HS, Zachary J, Paredes J,
Fessel WJ, Rhame F, Kramer F, Fischl MA, Poiesz B, Wood K, Ruprecht RM, Kim J, Grossberg SE,
Kasdan P, Berge P, Marshak A, Pettinelli C. Synergy, activity and tolerability of zidovudine and
interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Therapy 1996;
1(2):77-88.
111. Sacks HS, Reitman D, Pagano D, Kupelnick B. Meta-analysis: An Update. Mount Sinai J Med
1996;63:3-4.
112. Busch MP, Collier A, Gernsheimer T, Carrington JD, Flanigan TP, Kashkari M, Kennedy M,
Kumar PN, Lane TA, Mellors JW, Mohandas K, Pollard RB, Viele M, Yomtovian R, Holland PV,
McCurdy PR, and the VATS Group (incl. Sacks HS). The viral activation transfusion study (VATS):
rationale, objectives, and design overview. Transfusion 1996;36:854-859.
113. Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J, Stood E, Jemsek JG, LaMarca A,
Ramirez-Ronda C, Dellamonica P, Messina M, Cross A, Dunkle L, Smaldone L, and the Bristol-Myers
Squibb Stavudine/019 Study Group (incl. Sacks HS). Clinical efficacy of stavudine compared to
zidovudine in HIV-infected zidovudine-experienced patients. Ann Intern Med 1997;126:355-362.
114. Studies of Ocular Complications of AIDS research group in collaboration with the AIDS Clinical
Trials Group (incl. Sacks HS). Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS:
The HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann Intern Med
1997:126:264-274.
115. Marcus AM, Rose D, Sacks HS, Schechter CB. BCG vaccination to prevent tuberculosis in health
care workers. Preventive Medicine 1997;26:201-207.
116. Jiang JD, Schlesinger M, Sacks HS, Mildvan D, Roboz J, Bekesi G. Concentrations of soluble
11
CD95 and CD8 antigens in the plasma and level of CD8+CD95+CD8+CD38+and CD4+CD95+T cells
are markers for HIV-1 infection and clinical status. Journal of Clinical Immunology 1997;17:185-192.
117. Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus disease prevention in patients with
AIDS; oral ganciclovir and CMV PCR testing. AIDS 1997;11:883-887.
118. Englund JA, Baker CJ, Raskino C, and the Pediatric AIDS Clinical Trials Group (incl. Sacks HS.)
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J
Med 1997;336:1704-12.
119. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with
AIDS and CMV retinitis treated with foscarnet and ganciclovir. Studies of Ocular Complications of
AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group (incl. Sacks HS) J Inf Dis
1997;176:50-8.
120. Ioannidis JPA, Cappelleri JC, Melville B, Sacks HS, Lau J. The relationship between study design,
results and reporting of randomized clinical trials of HIV infection. Controlled Clin Trials 1997;18:431444.
121. Mechanick JI, Cobin, Sacks HS. Hypothalamic-pituitary axis dysfunction in critically ill patients
with a low free thryroxine index. J Endocrinol Invest 1997;20:462-70.
122. Ioannidis JPA, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Predictors and impact of
patients lost to follow-up in a long term randomized trial of immediate vs. deferred antiretroviral
treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:22-30.
123. Weinberg RS, Chusid E, Galperin Y, Thomson J, Cheung T, Sacks HS. Effect of antiviral drugs
and hematopoietic growth factors on in vitro erythropoiesis. Mt Sinai J Med 1998;65:5-13.
124. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Padian N,
Sacks HS, Feldman J, for the WIHS Collaborative Study Group. The Women's Interagency HIV Study
(WIHS)-design, methods, sample, cohort characteristics and comparison with reported AIDS cases in
U.S. women. Am J Epidemiol 1998; 9:117-25.
125. Hall CD, Dafni U, Simpson D, et al. and the AIDS Clinical Trials Group 243 Team (incl Sacks
HS). Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human
immunodeficiency virus infection. N Engl J Med 1998;338:1345-1351.
126. Chene G, Morlat P, Leport C, et al. and Members of the ANRS 005/ACTG 154 Trial Group (incl.
Sacks HS). Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of
pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV infected patients. Controlled Clinical
Trials 1998;19:233-248.
127. McIntosh K, Cooper E, Xu J, Mirochnick M, Lindsey J, Jacobus D, Mofenson L, Yogev R, Spector
SA, Sullivan JL, Sacks HS, Kovacs A, Nachman S, Sleasman J, Bonagura V, McNamara J, and members
of the ACTG 179 Study Team. Toxicity and efficacy of daily vs. weekly dapsone for prevention of
Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. Pediatr Infec
Dis J. 1999;18:432-9
128. Culnane M, Glenn FM, Lee SS, et al. and the ACTG 219/076 Trial Group (incl. Sacks HS). Lack
of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected
women. JAMA 1999;281:151-157.
129. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, Young M, Melnick S, Miotti P,
Burk R. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)positive and high-risk HIV-negative women. J Natl Cancer Inst 1999;91:226-236.
12
130. Stiehm ER, Lambert SJ, Mofenson LM, et al. and the ACTG 185 Study Group (incl. Sacks HS).
Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for
reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of
Pediatric AIDS Clinical Trials Group Protocol 185. J. Inf Diseases 1999;179:567-75.
131. Bell J, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-Infected people in subSaharan Africa is cost-effective. AIDS 1999;13:1549-1556.
132. Mofenson LM, Lambert SJ, Stiehm ER, et al. for the Pediatric ACTG Study 185 Team (incl. Sacks
HS). Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated
with zidovudine. N Engl J Med 1999;341:385-93.
133. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF for the QUOROM Group (incl.
Sacks HS). Improving the quality of reports of meta-analyses of randomised controlled trials: the
QUOROM statement. Lancet 1999;354:1896-900.
134. Berk PD, Sacks HS. Assessing the quality of randomized controlled trials: quality of design is not
the only relevant variable. Hepatology 1999 Nov; 30(5): 1332-4.
135. McArthur JC, Yiannoutsos C, Simpson DM, et al. For the ACTG 291 team. (incl. Sacks HS). A
phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology
2000;54:1080-1088.
136. Benson CA, Williams PL, Cohn DL, et al. and the ACTG 196 protocol team (incl. Sacks HS) .
Clarithromycin or rifabutin alone or in a combination for primary prophylaxis of Mycobacterium avium
complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. J. Inf
Diseases 2000;181:1289-97.
137. Kalish LA, Collier AC, Flanigan TP, Kumar PN, for the Viral Activation Transfusion Study Group
(incl. Sacks HS). Plasma human immunodeficiency virus (HIV) type 1 RNA load in men and women
with advanced HIV-1 disease. J. Inf Diseases 2000;182:603-6.
138.Haas DW, Fessel WJ, Delapenha RA, et al, and the Collaborative Protocol 020 Study Group (incl.
Sacks HS). Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reversetranscriptase inhibitor experience: A randomized, double-blind, placebo-controlled trial. J. Inf Diseases
2001;183:392-400.
139. Philpott S, Burger H, Anastos K, Ramirez C, Robison E, Meyer WA III, Sacks HS, Mathur U,
Castro R, Brunner C, Weiser B. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral
therapy. J. Clin Invest 2001;107:431-38.
140. Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman
MM, Murphy EL, Kumar P, Kelley M, Flanigan T, McMahon D, Sacks HS, Kennedy MS, Holland PV.
Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency
virus infection: the Viral Activation Transfusion Study a randomized, controlled trial.
JAMA
2001;285:1592-1601.
141. Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL, and the Viral Activation Transfusion
Study Group (incl. Sacks HS). Correlates of change in cytomegalovirus viremia in patients with
advanced human immunodeficiency virus infection who require transfusion.
J. Inf Diseases
2001;183:1573-7.
142. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks H S, Coller B. Outpatient
treatment of deep vein thrombosis in diverse inner-city patients. Am J Med 2001;110:458-62.
13
143.Wilson TE, Barron Y, Cohen M, Richardson J, Greenblatt R, Sacks HS, Young M, for the Women's
Interagency HIV Study. .Adherence to antiretroviral therapy and its association with sexual behavior in a
national sample of women with Human Immunodeficiency Virus. Clin Inf Diseases 2002;34:529-534.
144. Preston-Martin S, Kirstein LM, Pogoda JM, Rimer B, Melnick S, Masri-Lavine L, Silver S, Hessol
N, French AL, Feldman J, Sacks HS, Deely M, Levine AM. Use of mammography screening by HIVInfected women in the Women's Interagency HIV Study (WIHS). Preventive Medicine 2002;34:386-392.
145. Carmody ER, Diaz T, Starling P, Rocha Beruth dos Santos AP, Sacks HS. An evaluation of
antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic. Tropical Medicine and International
Health. 2003; 8:378-385.
146. Palacio H, Fox KJ, Wilson TE, Richardson J, Sacks HS, Cohen M, Young M, Munoz A. Women’s
Interagency HIV Study (WIHS). Healthcare use by varied highly active antiretroviral therapy (HAART)
strata: HAART use, discontinuation, and naivety. AIDS. 2004 Mar 5;18(4):621-30.
147. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl
MA, Pollard RB, Delapenha R, Gedeon L, van der Horst, C, Murphy RL, Becker MI, D'Aquila RT, Vella
S, Merigan TC, Hirsch MS, for the AIDS Clinical Trials Group Team (incl. Sacks HS). Comparison of
Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl J Med 2003; 349:2293303.
148. Shafer RW, Smeaton LM, Robbins GK, De Grutolla V, Snyder SW, D'Aquila RT, Johnson VA,
Morse G D, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD,
Stefano V, Hirsch MS, Merigan TC, for the AIDS Clinical Trials Group 384 Team (incl. Sacks HS)
Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for
HIV-1 Infection. N Engl J Med 2003;349:2304-15.
149. Ahdieh-Grant L, Li R, Levin AM, Massad LS, Strickler HD, Minkoff H, Moxley M, Palefsky J,
Sacks HS, Gange SJ. Use of highly active antiretroviral therapy and the regression of cervical squamous
intraepitheial lesions in women infected with human immunodeficiency virus. J. Natl Cancer Inst.
2004;96:1051-3
150. Massad LS, Silverberg M, Springer G, Minkoff H, Hessol N, Palefsky J, Strickler H, Levine A,
Sacks HS, Moxley M, Minkoff H, Watts H, Weber K, Cohen M. Effect of antiretroviral therapy on the
incidence of genital warts and vulvar neoplasia on women with HIV. Am J Obstet Gynecol 2004; 190:
1241-8.
151. Hessol NA, Seaberg EC, Preston-Martin S, Massad LS, Sacks HS, Silver S, Melnick S, Abulafia O,
Levine AM. Cancer risk among participants in the Women's Interagency HIV Study. J. Acquir Immune
Defic Syndr 2004; 36: 978-85.
152. Wisnivesky JP, Serebrisky D, Moore C, Sacks HS, Iannuzzi MC, McGinn T. Validity of
clinical prediction rules for isolating inpatients with suspected tuberculosis. A systematic review. J Gen
Intern Med. 2005; 20(10) :947-52.
153. Dunn AS, Wisnivesky J, HoW, Moore C, McGinn T, Sacks HS. Perioperative Management of
Patients on Oral Anticoagulants: A Decision Analysis. Medical Decision Making 2005; 25: 387-397.
154. Sacks HS. Review: vaccination reduces the incidences of serologically confirmed influenza in
healthy adults. ACP J Club. 2005 May-Jun; 142(3): 70.
155. Sacks HS. A nurse-led clinical pathway reduced hospitalizations in nursing home residents with
pneumonia ACP J Club. 2006 Nov-Dec ;145(3);81.
156. Kohli R, Klein RS, Schoenbaum EE, Anastos K, Minkoff H, Sacks H. Aging and HIV infection. J
14
Urban Health. 2006 Jan;83(1):31-42
157. Baban K, Ikeda S, Pooran D, Hennig N, Indyk D, Sacks H, Carter G. Culture, community networks
and HIV/AIDS outreach opportunities in a south Indian Siddha organization. Soc Work Health Care.
2006;42(3-4):77-92.
158. Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON- TB
infection in HIV –infected individuals. Int J Tuberc Lung Dis. 2007 Nov;11(11):1190-5.
159. Sacks HS. Encouraging influenza vaccination for nursing home staff reduced mortality and
influenza like illness in the residents. Evid Based Med. 2007 Jun;12(3):81.
160. Sacks HS. Encouraging influenza vaccination for nursing home staff reduced mortality and
influenza-like illness in the residents. ACP J Club. 2007 May-Jun;146(3):61.
161. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, Di Giambenedetto S,
Cingolani A, Taoufik Y, Miralles P, Marra CM, Antinori A; Gesida 9/99, IRINA, ACTG 363 Study
Groups (incl Sacks H). Cidofovir in addition to antiretroviral treatment is not effective for AIDSassociated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008 Sep
12;22(14):1759-67.
162. Sacks HS. CD4+ count-guided antiretroviral therapy interruption increased opportunistic disease
and death more than continuous therapy in HIV. Evidence-Based Medicine 2009;14:16.
163. Lowy I, Molrine DC, Leav BA et al.(incl Sacks H). Treatment with Monoclonal Antibodies against
Clostridium difficile Toxins. N Engl J Med 2010;362:197-205.
164. Crowley LE, Herbert R, Moline JM, Wallenstein S, Shukla G, Schechter C, Skloot GS, Udasin I,
Luft BJ, Harrison D, Shapiro M, Wong K, Sacks HS, Landrigan PJ, Teirstein AS."Sarcoid like"
granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med. 2010 Dec
22. [Epub ahead of print] (http://onlinelibrary.wiley.com/doi/10.1002/ajim.20924/pdf).
165. Sacks HS. Dexamethasone reduced length of hospital stay in patients with community-acquired
pneumonia. ACP Journal Club. Ann Intern Med. 2011 Sep 20;155:JC3-6.
166. Rhodes R, Azzouni J, Baumrin SB, Benkov K, Blaser MJ, Brenner B, Dauben JW, Earle WJ, Frank
L, Gligorov N, Goldfarb J, Hirschhorn K, Hirschhorn R, Holzman I, Indyk D, Jabs EW, Lackey DP,
Moros DA, Philpott S, Rhodes ME, Richardson LD, Sacks HS, Schwab A, Sperling R, Trusko B, Zweig
A. De minimis risk: a proposal for a new category of research risk. Am J Bioeth. 2011 Nov;11(11):1-7.
167. Sacks HS. Influenza vaccination reduced cardiovascular events in patients hospitalized with an acute
coronary syndrome. ACP Journal Club. Ann Intern Med. 2011 Nov 15;155(10):JC5-05. PubMed PMID:
22084352.
168. Sacks HS. Adding procalcitonin-guided therapy to standard care did not reduce mortality in
critically ill patients. ACP Journal Club. Ann Int Med. 2012 Feb 21:156(4);JC2-6.
15
Abstracts and Presentations
1. Brostoff S, Sacks HS, DalCanto M, Johnson A, Raine C, Wisniewski H. Chemical and
immunological properties of the P-2 protein from bovine root myelin. Trans Am Soc Neurochem
1974;5:165. Presented Am Soc Neurochem, Atlantic City, NJ, Nov., 1974.
2. Anish D, Baum M, Chalmers TC, Sacks HS, Smith H. Prophylactic antibiotics in colon surgery: The
use and misuse of no-treatment controls. Clin Res 1980;28:540A. Presented Am Fed Clin Res,
Washington, DC, April,1980.
3.
Chalmers TC, Sacks HS, Smith H. Historical versus randomized controls for clinical
trials. Controlled Clin Trials 1980;1:177. Presented Soc Clinical Trials, Philadelphia, PA, April, 1980.
4. Sacks HS, Chalmers TC, Smith H. Sensitivity and specificity of clinical trials: Randomized
vs. historical controls. Clin Res 1981;29:259A. Presented Am Fed Clin Res, San Francisco, CA, April,
1981.
5. Celano P, Chalmers TC, Sacks HS, Smith H. Treatment assignments bias in controlled clinical
trials. Controlled Clin Trials 1981; 2:76. Presented Soc for Clinical Trials, San Francisco, CA, May,
1981.
6. Moskowitz G, Chalmers TC, Sacks HS, Fagerstrom R, Smith H. Deficiencies of controlled trials of
alcohol withdrawal. Alcoholism Clin and Exp Res, 1981;5:162. Presented Nat Council on Alcoholism,
New Orleans, LA, April, 1981.
7. Cohen B, Chalmers TC, Sacks HS, Fagerstrom R. Time-related events are handled badly in clinical
trials. Clin Res 1981;29:255A. Presented Am Fed Clin Res, San Francisco, CA, April, 1981.
8. Celano P, Chalmers TC, Sacks HS, Smith H. Call for a registry of randomized acute myocardial
infarction patients. Clin Res 1981;29:562A.
9. Fagerstrom R, Smith H, Sacks HS, Cohen B. Use of jackknife techniques in determining a "best"
subset of covariates for the Cox proportional-hazards model. Controlled Clin Trials
1981;2:88. Presented Soc Clinical Trials, San Francisco, CA. May, 1981.
10. Kirschner E, Chalmers TC, Popper H, Gerber M, Stenger R, Goldberg J, Sacks HS. Observer error in
biopsy interpretations and outcome in chronic hepatitis. Gastroenterol 1981;80:360. Presented Am
Gastroenterol Assoc., New York, N.Y. May, 1981.
11. Pianko L, Sherman F, Rehr H, Sacks HS. Acceptance of pneumococcal vaccination by the
community residing elderly. Gerontologist 1981;21:240-241. Presented Gerontological Society of
America, Toronto, Canada, Nov. 1981.
12. Caroscio JT, Kochwa S, Sacks HS, Cohen J, Yahr M. Cerebrospinal fluid IgG and albumin indices in
multiple sclerosis and other neurological diseases. J Clin Chem Clin Biochem 1981;19:630. Presented
XI Int Cong Clin Chem, Vienna, Austria, September, 1981.
13. Moskowitz G, Sacks HS, Chalmers TC. Impact of randomized control trials on the treatment of
alcohol withdrawal. Alcoholism Clin Exp Res 1981;6:149. Presented National Council on Alcoholism,
Washington, DC, April, 1982.
14. Chan SS, Sacks HS, Chalmers TC. Stopping rules in randomized control trials. Controlled Clinical
Trials 1981:3:153. Presented Soc for Clin Trials, Pittsburgh, PA., May, l982.
15. Chan SS, Sacks HS, Chalmers TC. The epidemiology of unpublished randomized control trials. Clin
Res 1981;30:234A. Presented Am Fed Clin Res, Washington, DC, May, 1982.
16
16. Messer J, Sacks HS, Reitman D, Chalmers TC. Corticosteroids do cause peptic ulcer
disease. Gastroenterol 1982;82:1130. Presented Am Gastroenterol Assn., Chicago, Ill., May, 1982.
17. Wolke A, Brooks K, Sacks HS, Schaffner F. Extra-hepatic malignancy and atherosclerosis in
primary biliary cirrhosis. Gastroenterology 1982;82:1212.
18. Chalmers TC, Reitman D, Koffler A, Sacks HS. Bias in the interpretations of clinical trials. Clin Res
1982;30:549A.
19. Sacks HS, Weinstein R, Chalmers TC. Deficiencies of clinical trials in malaria. Presented VIII Int
Cong Infectious and Parasitic Diseases, Stockholm, Sweden, June, 1982.
20. Sacks HS, Weinstein R, Chalmers TC. Deficiencies of clinical trials in schistosomiasis. Mol
Biochem Parasitol 1982; Suppl:513-514. Presented Fifth Int Cong Parasitol, Toronto, Canada, Aug.,
1982.
21. Sherman FT, Sacks HS, Pianko L. Physician knowledge and usage of pneumococcal and influenza
vaccines in the elderly. Gerontologist 1982;22:119. Presented Gerontol Society of America, Boston,
MA., Nov. 1982.
22. Messer J, Reitman D, Sacks HS, Chalmers TC. Steroids, variceal bleeding and clinical
opinions. Hepatology 1982;2:738.
23. Schaffner F, Sternlieb I, Sacks HS. A two dose level randomized double blind controlled trial of
penicillamine in primary biliary cirrhosis. Hepatology 1982;2:714.
24. Sacks HS, Chalmers TC, Smith H. The Chalmers method for analyzing clinical trial reports. In, Le
Rapport de L'Essai Clinique. Boissel JP, et al. (eds.), SIMEP, Lyon, 1983. pp 74-76. Presented 2eme
Seminaire sur les Essais Controles,Lyon, France, September, 1982. (Invited Presentation)
25. Sacks HS, Reitman D, Chalmers TC, Smith H. The effect of unpublished studies (the file drawer
problem) on decisions about therapeutic efficacy. Clin Res 1983;31:236A. Presented Am Fed Clin Res,
Washington, DC, May, 1983.
26. Mak N, Chalmers TC, Moskowitz G, Sacks HS, Smith H. Good technology and poor clinical
science. Clin Res 1983;31:525A. Presented Assoc Am Physicians, Washington, DC, May, 1983.
27. Sacks HS. The impact of clinical trials on the practice of medicine. Presented Soc Clinical Trials, St.
Louis, MO, May, 1983. (Invited presentation)
28. Wiesel J, Rose DM, Silver AL, Sacks HS, Bernstein RH. Lumbar puncture in late-latent syphilis: An
analysis of the benefits and risks of testing for asymptomatic neurosyphilis. Medical Decision Making
1983; 3:378. Presented Soc for Med Decision Making. Toronto, Can., October, 1983.
29. Mathur U, Enlow RW, Spigland I, Winchester RJ, Rorat E, Sacks HS, Klein MJ, Mildvan D.
Parasitic, avian tuberculosis and other infections: Place in immunologic disease. Presented NY Acad Sci
Conference on Acquired Immune Deficiency Syndrome. New York, NY, November, 1983.
30. Meyers BR, Srulevitch ES, Sacks HS, Hirschman SZ, Worner T, Wormser GP, Jacobson
J. Pharmacokinetics of mezlocillin in patients with varying degrees of hepato-biliary dysfunction. In,
Proc l3 Int Cong Chemotherapy. Spitzy KH, Karrer K. (eds.). Vienna, Austria. Aug., 1983. pp 19-29.
31. Mak N, Chalmers TC, Sacks HS. Inadequate evaluations of therapeutic apheresis. Clin Res 1984;
32:227A. Presented Am Fed Clin Res. Washington, DC, May 1984.
32. Bhaskar R, Sacks HS, Chalmers TC. Handling of patient dropouts in trials measuring long-term
17
survival. Controlled Clinical Trials 1984;5:306. Presented Soc for Clinical Trials, Miami, Fla. May
1984.
33. Chalfin DB, Sacks HS, Chalmers TC. Deficiencies of clinical trials in Alzheimer's disease.
Gerontologist 1984;24:97-98. Presented Gerontol. Soc. of America, San Antonio, Tx., Nov. 1984.
34. Kussin P, Sacks HS, Chalmers TC. Has the Feingold diet been adequately evaluated? meta-analysis
of randomized control trials of defined diet in the treatment of childhood hyperactivity. Presented Amer
Acad of Child Psych, Toronto, Canada Oct, 1984.
35. Finley S, Reitman D, Chalmers TC, Sacks HS. Meta-analysis of randomized control trials (RCTs) of
sclerotherapy for esophageal varices. Gastroenterology 1985;88(5):1658.
36. Kussin P, Sacks HS, Chalmers TC. Stress ulcer prophylaxis in the critically ill: Quality assessment
and meta-analysis of randomized control trials. Gastroenterology 1985;88:1715. Presented Am
Gastroenterol Assoc. New York, NY, May 1985.
37. Sacks HS, Berrier J, Chalmers TC. Meta-analysis of therapies for myocardial infarction. Presented
Int Symposium for Cardiovascular Pharmacotherapy, Geneva, Switzerland, April 1985.
38. Sacks HS, Chalmers TC. Meta-analyses of randomized control
1985;33:525A. Presented Am Soc Clin Invest, Washington, D.C., May 1985.
trials.
Clin
Res
39. Rosen MJ, Ghows MB, Sacks HS, Chuang MI. Transcutaneous oxygen monitoring during fiberoptic
bronschoscopy. Am Rev Resp Dis 1985;131:A119.40. Sacks HS. General Principles - The challenge of
Meta-Analysis. Symposium, Versailles, France, October 1985. (Invited Presentation).
41. Lam W, Sacks HS, Chalmers TC. Meta-analysis of randomized control trials of nicotine chewing
gum. Clin Res 34:824A, 1986.
42. Ancona-Berk VA, Sacks HS, Chalmers TC. The economic content of meta-analyses. Clin Res
34:710A, 1986.
43. Levin HR, Sacks HS, Chalmers TC. Can meta-analysis of many small trials substitute for
performing large trials? Clin Res 34:635A, 1986. Presented Am Soc Clin Invest, Washington, D.C., May
1986.
44. Sze PC, Pincus M, Sacks HS, Chalmers TC. Anti-platelet agents and secondary stroke prevention:
A meta-analysis of the randomized control trials. Clin Res 34:385A, 1986. Presented Am Fed Clin Res,
Washington, D.C., May 1986.
45. Sacks HS, Reitman D, Berrier J. Technical quality assessment of therapeutic research in AIDS.
Presented 2nd International Conference on AIDS, Paris, France, June, 1986.
46. Neibart E, Masci J, Nicholas P, Sacks HS. Malaria at an urban hospital in New York City (NYC).
Presented Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La,
October, 1986.
47. Neibart E, Sacks HS, Hammer G, Hirschman SZ. Difluoromethylornithine (DFMO) in the treatment
of Pneumocystis carinii pneumonia (PCP). Presented Interscience Conference on Antimicrobial Agents
and Chemotherapy, New Orleans, La, October, 1986.
48. Levine J, Sacks HS, Mulvihill M, Neufeld R, Libow LS. Correlation of nutritional status with
oropharyngeal colonization in elderly SNF residents. Presented AGS/AFAR Annual Meeting, New
Orleans, La. May 15, 1987.
18
49. Wu AW, Rubin HR, Sacks HS, Rosen MJ. The outcome of medical intensive care in the elderly;
validation of Apache II in a retrospective analysis. Critical Care Medicine 15:381,1987. Presented
Society for Critical Care Medicine, Anaheim, CA, May 1987.
50. Berlin JA, Laird NM, Sacks HS, Chalmers TC. Comparison of statistical methods for combining
event rates from clinical trials. Controlled Clinical Trials 1987;8. Presented Soc for Clin Trials, Atlanta,
GA, May, 1987.
51. Reitman D, Sacks HS, Chalmers TC. Technical quality assessment of randomized control trials
(RCTs). Controlled Clin Trials 1987;8. Presented Soc for Clin Trials, Atlanta, GA, May, 1987.
52. Isenberg Y, Libow L, Sacks HS, Neufeld R. Bacteremia Study. Presented Geriatric Society of
America, Washington, DC, October, 1987.
53. Jacobson JM, Worner TM, Sacks HS, Lieber CS. Human immunodeficiency virus (HIV) and
Hepatitis B virus (HBV) infections in an alcoholic population. Presented American Medical Society on
Alcohol and Other Drug Dependency, Washington, DC, April, 1988.
54. Chalmers TC, Berrier J, Hewitt P, Reitman D, Nagalingam R, Sacks HS. Logistics of determining
rates of rare side-effects by meta-analysis. Presented Soc Clin Trials. San Diego, CA, May 1988.
55. Reitman D, Chalmers TC, Nagalingam R, Sacks HS. Can efficacy of blinding in randomized control
trials (RCTs) be documented by meta-analysis? Presented Soc Clin Trials. San Diego, CA, May 1988.
56. Sacks HS, Reitman D, Berrier J. Technical quality assessment of therapeutic research in AIDS.
Presented IV International Conference on AIDS. Book 1, Page 251, Abstract #3126, Stockholm, Sweden,
June 1988.
57. Sperling R, Sacks HS, Mayer L, Berkowitz R. Serosurvey of an obstetrical population in a voluntary
hospital in New York City. Presented IV International Conference on AIDS. Book 1, Page 267, Abstract
#4030, Stockholm, Sweden, June 1988.
58. Rubin HC, Reitman D, Berrier J, Sacks HS. Attitudes about human immunodeficiency virus (HIV)
among health care workers and medical students. Presented American Public Health Association,
November, 1988.
59. Rose DN, Sacks HS. Zidovudine prophylaxis for persons with accidental percutaneous blood
exposure: A decision analysis. Presented V International Conference on AIDS. Page 148, Abstract ThAP
45, Montreal, Canada, June, 1989.
60. Sacks HS, Martin J. Ethical and legal issues in clinical trials for HIV-infected children. Presented V
International Conference on AIDS. Page 963, Abstract WFP 3, Montreal, Canada, June, 1989.
61. Sacks HS, Rubin H. Community-based care for people with HIV disease. Presented V International
Conference on AIDS. Page 845, Abstract MEP 72, Montreal, Canada, June, 1989.
62. Fahs M, Strain J, Fulop G, Sacks HS, Padgug R, Eisenhandler J. Longitudinal hospital use and
charges of scatter bed and AIDS cluster unit inpatients. Presented V International Conference on AIDS.
Page 1030, Abstract MHO 9, Montreal, Canada, June, 1989.
63. Neibart EP, Dembitzer F, Hammer GS, Dembitzer R, Sacks HS, Hirschman SZ. Eflornithine in the
treatment of Pneumocystis Carinii pneumonia (PCP). Presented V International Conference on AIDS.
Page 291, Abstract TBP 29, Montreal, Canada, June, 1989.
64. Wallace JL, Beatrice S, Sacks HS. Routine laboratory tests which correlate with HIV-I infection
prior to onset of AIDS. Presented V International Conference on AIDS. Page 366, Abstract WBP 88,
19
Montreal, Canada, June, 1989.
65. Mildvan D, Armstrong D, Antoniskis D, Sacks HS, Balfour H, Buzas J, Petinelli C. An open label
dose-ranging trial of AL721 in PGL and ARC. Presented V International Conference on AIDS. Page
403, Abstract WBP 312, Montreal, Canada, June, 1989.
66. Duke SI, Drucker E, Guillette P, Sacks HS. Collaborative evaluation study of AIDS training
programs for women's health providers. Presented V International Conference on AIDS. Page 718,
Abstract MDP 45, Montreal, Canada, June, 1989.
67. Fulop G, Strain J, Fahs M, Sacks HS. Scatter bed versus cluster unit treatment of AIDS inpatients.
Presented V Intl Conference on AIDS. Page 1045, Abstract THP 7, Montreal, Canada, June, 1989.
68. Lefkowitz-Korenblit P, Foley M, Epstein I, Sperling R, Martas M, Rothenberg A, Indyk D, Sacks HS.
Experiences of a hospital AIDS education program: Lessons learned. Third International AIDS
Education Conference, Nashville, Tennessee, September, 1989.
69. Reitman D, Brown WD, Kannry JL, Sacks HS, Chalmers TC. Are women under-represented in
randomized control trials (RCT's)? Presented Am Pub Health Assn, Chicago, Il, October, 1989.
70. Fahs M, Strain J, Fulop G, Sacks HS, Padgug R, Eisenhandler J. Hospital models of care: Scatter
bed vs AIDS cluster unit. Presented Am Pub Health Assn, Chicago, Il, October, 1989.
71. Kornbluth A, Salomon P, Sacks HS, Janowitz HD. How effective are current drugs for ulcerative
colitis? Presented American Gastroenterological Association, San Antonio, TX, May, 1990.
72. Squires K, Weiss W, Sacks HS, Hassett J, Gugliotti R, Murray H. Phase I trial of 2'3'-didehydro-3'deoxythymidine (d4T) in patients with AIDS or ARC. Clin Res 1990;380:280A. Presented Am Fed Clin
Res, Washington, D.C., May, 1990.
73. Squires K, Weiss W, Sacks HS, Hassett J, Gugliotti R, Murray H. Effect of 2'3'-Didehydro-3'deoxythymidine (d4T) on p24 antigenemia in patients with AIDS or ARC. Abstract Th.A. 241. V.1;
p.180. Presented VI Int Conf on AIDS. San Francisco, CA, June, 1990.
74. Cheung TW ,Fahs M, & Sacks HS. Cost-Effectiveness Analysis of Early Treatment of HIV Disease
with Zidovudine (AZT), presented VI Int'l Conf. AIDS, San Francisco,June 1990[abs.4078].
75. Fahs M, Fulop G, Strain J, Sacks HS, Turner B. Alternate models of hospital care for AIDS patients
determinants of cost and quality. Health Services Research and Public Policy 1990:13. Presented VII
Annual Meeting of the Association for Health Services Research, Arlington, VA, June, 1990.
76. Sacks HS, Rose D. Zidovudine prophylaxis for needlestick exposure to human immunodeficiency
virus: a decision analysis. Theor Surg 5(3):165(1990). Presented Third Conference of the European
Society for Medical Decision Making, Glasgow, Scotland, June, 1990.
77. Duke SI, Goldberg JL, Drucker E, Epstein I, Sacks HS, Gillette P. Attitudes toward perceived risk
populations as predictors of provider AIDS education services to MCH clients. Presented American
Public Health Association Meeting, New York, NY, October, 1990.
78. Seremitis S, Aledort LM, Sacks HS, and the Monoclate Study Group. Differential effects on CD4
cell counts of high or intermediate purity factor VIII concentrates in HIV+ hemophiliacs. Presented at the
Amer Soc of Hematol, Boston, MA, November, 1990.
79. Weinberg RS, Thomson JC, Sacks HS, Cheung T, Chusid ED. AIDS Drugs 3'-Azido-3'Deoxythymidine (AZT), 2'3'-Dideoxyinosine (ddI), and 2'3'-Dihydro-3'-Deoxythymidine (d4T) inhibit
erythropoiesis in vitro. Presented Amer Soc of Hematol, Boston, MA, November, 1990.
20
80. Rose DN, Schechter CB, Sacks HS. Prevention of tuberculosis among patients infected with human
immunodeficiency virus. Presented SGIM 14th Annual Meeting, Seattle, WA, May, 1991.
81. Warford R, Rando-Chanon R, Barzilai A, Sacks HS. Clinical dilemmas and strategies engaging
HIV+ mother-child pairs in consistent health care. Presented VII International Conference on AIDS,
Florence, Italy, June, 1991.
82. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination for HIV-infected
patients; a policy analysis. Presented VII International Conference on AIDS, Florence, Italy, June, 1991.
83. Barzilai A, Hodes D, Birnbaum M, Heon D, Warford R, Rando-Chanon R, Sacks HS. Effect of
participation in a clinical trial on compliance and patient care costs for children with AIDS. Presented
VII International Conference on AIDS, Florence, Italy, June, 1991.
84. Weinberg RS, Galperin Y, Chusid ED, Niebart D, Cheung T, Sacks HS. Erythropoiesis in HIV
infected (HIV+) patients: in vitro response to AIDS drugs is different than normal. Retro Dis Abstract
1437, p.362a. Presented American Society of Hematology, Denver, CO, December, 1991.
85. Weinberg RS, Chusid ED, Galperin Y, Cheung T, Sacks HS. Stem cell factor stimulates in vitro
growth of erythroid progenitor cells from HIV+ patients. Clin Res 1992;40(2):242A. Presented American
Federation Clinical Research, Washington, DC, May, 1992.
86. Sacks HS, Chalmers TC, Reitman D, Lau TS. Is the antiplatelet effect of aspirin enhanced by
dipyridamole? A meta-analysis. Clin Res 1992;40(2):304A. Presented American Federation Clinical
Research, Washington, DC, May, 1992.
87. Chalmers TC, Lau J, Sacks HS. When should randomization to untreated control groups stop?
Abstract A9. Presented 13th Annual Meeting Society for Clinical Trials, Philadelphia, PA, May, 1992.
88. Stein D, Corey L, Volberding P, Jermano J, Dixon D, Feldstein M, Flexner C, Freeman D, Sacks HS,
et al. Preliminary safety and activity evaluation of new agents for the treatment of HIV-1 infection:
recommended guidelines for trial design. Abstract A28. Presented 13th Annual Meeting Society for
Clinical Trials, Philadelphia, PA, May, 1992.
89. Squires K, Sacks HS, Sledz S, Murray H. Findings from a phase I study of stavudine (d4T).
Abstract PoB 3030. Presented VIII International Conference on AIDS/III STD World Congress,
Amsterdam, The Netherlands, July, 1992.
90. Petersen E, Ramirez-Ronda C, Schwartz R, Peterson D, Hardy W, Sacks HS, Follansbee S. Findings
from a phase II study of stavudine (d4T). Abstract PoB 3023. Presented VIII International Conference
on AIDS/III STD World Congress, Amsterdam, The Netherlands, July, 1992.
91. Szabo S, Miller LH, Sacks HS. Gender differences in the natural history of HIV infection.
Presented VIII International Conference on AIDS/III STD World Congress, Amsterdam, The
Netherlands, July, 1992.
92. Cheung TW, Fahs M, Sacks HS. Cost-effectiveness of ganciclovir (DHPG) versus foscarnet (FOS)
for cytomegalovirus (CMV) retinitis in patients with AIDS. Presented VIII Intl Conference on AIDS/III
SID World Congress, Amsterdam, The Netherlands, July, 1992.
93. Gurtman AC, Szabo S, Rose D, Mayer H, Sacks HS. Comparison of Clostridium difficile diarrhea
(CdD) in hospitalized HIV seropositive (HIV+) and HIV seronegative (HIV-) patients (pts). Presented
ICAAC 32nd Annual Meeting, Anaheim, CA, October, 1992.
94. Short L, Schechter C, Meyers B, Rodriguez M, Cohen S, Lozada J, Button G, Sacks HS, Decambre
21
M, Landrigan P, Hirschman SZ. Comparative cross-over study of a needleless heparin lock system vs a
conventional heparin lock: Impact on complications, sharps injuries, and cost. Presented ICAAC,
Anaheim, CA, October, 1992.
95. Indyk D, Rier D, Belville R, Sacks HS, Chusid E, Sweeney M, Garson J. Community partnerships
for service, education and AIDS clinical trials. Oral presentation, Bioethics. Section. Presented American
Public Health Association Conference, Washington, DC, November, 1992.
96. Cheung TW, Wallach F, Cohen S, Sacks HS, Complications of adjuvant steroid therapy for
presumed Pneumocystis cariniii pneumonia (PCP) in an innercity population. Presented ICAAC, New
Orleans, Louisiana, October 1993.
97. Weinberg RS, Chusid ED, Galperin Y, Cheung T, Sacks HS. Stem cell factor and IL-3 stimulate in
vitro growth of erythroid progenitor cells from HIV + patients. Presented IXth International Conference
on AIDS, Berlin, June 7-11, 1993.
98. Gross PA, Hermogenes A, Sacks HS, Levandowski RA, The protective efficacy of influenza vaccine
in the elderly: A Meta-analysis. Presented 34th ICAAC, Orlando,Fl.,October 1994.
99. Singh P, Rose DN, Sacks HS. Rifabutin prophylaxis for prevention of Mycobacterium avium
infection: Decision analysis and cost-effectiveness analysis. Presented Second National Conference on
Human Retroviruses and Related Infections, Washington D.C. January 1995.
100. Ioannidis JPA, Cappelleri JC, Sacks HS, Lau J. Early or deferred zidovudine in HIV-infected
patients without an AIDS-defining illness: A Meta-analysis. Presented Second National Conference on
Human Retroviruses and Related Infections, Washington D.C. January, 1995.
101. Sacks HS, Rose DN. Cost-effectiveness of HIV treatment and prevention. Presented Ciba
Foundation Symposium: New Directions in AIDS Research, London, England. Nov, 1995 (Invited
presentation).
102. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A dose-response meta-analysis of
Pneumocystis carinii prophylaxis. Presented Third National Conference on Human Retroviruses and
Related Infections, Washington, D.C., January, 1996.
103. Ioannidis JPA, Cappelleri JC, Sacks HS, Skolnik PR. A model of the predictive value of viral load
measurements in asymptomatic untreated HIV-1 infection. Presented Third National Conference on
Human Retroviruses and Related Infections, Washington, D.C., January, 1996.
104. Rose DN, Sacks HS, Lan V. Cost-effectiveness analysis of oral ganciclovir to prevent
cytomegalovirus disease in patients with AIDS. Presented XI International Conference on AIDS and
STDs. Vancouver, July, 1996.
105. Barkan S, Preston-Martin S, Kalish L, Melnick S, Weber K, Sacks HS, Marx E, Padian N, Feldman
J, for WIHS Collaborative Study Group. The Women's Interagency HIV Study (WIHS)-Characteristics
and comparisons with AIDS cases in United States women. Presented XI International Conference on
AIDS and STDs. Vancouver, July, 1996.
106. Barkan S, Melnick S, Stonis L, Preston-Martin S, Sacks HS, Marx E, Padian N, Feldman J, WIHS
Collaborative Study Group. The Women's Interagency HIV Study (WIHS)-I. Design, method, sample.
Presented XI International Conference on AIDS and STDs. Vancouver, July, 1996.
107. Ioannidis JP, Cappelleri JC, Melville B, Sacks HS, Lau J. Effect of study design factors on the
treatment effect of HIV trials. Presented XI International Conference on AIDS and STDs. Vancouver,
July, 1996.
22
108. Cheung TW, Estok L, Rose D, Chusid E, Choi K, Sacks HS. Carcinoma of the lung in HIV-positive
patients. Presented XI International Conference on AIDS and STDs. Vancouver, July, 1996.
109. Cheung TW, Cohen S, Gurtman A, Sacks HS. Cervical dysplasia in HIV-infected women in an
inner city population. Presented XI International Conference on AIDS and STDs. Vancouver, July, 1996.
110. Sacks HS. Meta-Analysis. Presented 40th Nestle' Nutrition Workshop. Washington D.C.,
September, 1996. (Invited Presentation).
111. Bell J, Sacks HS. Cost-effectiveness analysis of vitamin A supplementation to reduce perinatal
transmission of HIV in developing countries. Presented 4th Conference on Retroviruses and
Opportunistic Infections. Washington, D.C., January, 1997.
112. Ioannidis JPA, Sacks HS, Cappelleri JC, Lau J. Clinical efficacy of antiretroviral changes in
treatment-experienced HIV-infected patients: A meta-analysis. Presented 4th Conference on Retroviruses
and Opportunistic Infections. Washington, D.C., January, 1997.
113. Ioannidis JPA, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Predictors and impact of
patients lost to follow-up in a long term randomized trial of immediate vs. deferred antiretroviral
treatment. Presented 4th Conference on Retroviruses and Opportunistic Infections. Washington, D.C.,
January, 1997.
114. Ioannidis JPA, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Evaluation of predictors
and impact of losses to follow-up in the domain of HIV infection. Presented at Second Joint Meeting of
the Society for Clinical Trials and the International Society for Clinical Biostatistics. Boston, MA, July
1997. Controlled Clinical Trials 1997;18:101S.
115. Palefsky J, Minkoff H, Kalish LA, Levine A, Garcia P, Young M, Melnick S, Miotti P, Burk R,
Sacks HS. Cervicovaginal human papillomavirus infection in HIV-positive and high risk HIV-negative
women. Natl Conf Women HIV. 1997 May 4-7;127 (abstract no. 203.3).
116. Bell J, Rose DN, Sacks HS. Cost-effectiveness of isoniazid preventive therapy for HIV-infected
people in sub-Saharan Africa. Presented 12th World AIDS Conference, Geneva, Switzerland, July,
1998.
117. Ohmit S, Schuman P, Schoenbaum E, Rompalo A, Cohen M, Richardson J, Sacks HS, Young M.
Adherence to antiretroviral therapy (ART) among women in the HIV Epidemiology research study
(HERS) and women=s Inter-Agency HIV study (WIHS). Presented Int Conf AIDS July, 1998;12:590
(abstract no.32347).
118. Gersony DR, McLaughlin MA, Sacks HS, Fuster V, Gersony WM. Effect of beta blocker therapy
on clinical outcome in patients with Marfan syndrome: Meta-analysis of data from 802 patients.
Presented at American College of Cardiology, New Orleans, LA March, 1999 (abstract no.1074-70).
119. Schuman P, Ohmit SE, Cohen M, Sacks HS, Schoenbaum E, Rompalo A, Richardson J, Young M,
DaVenny K. Prescription of anti-retroviral therapy by health care providers to women: report from the
HIV Epidemiology Research Study (HERS) and Women’s Inter-Agency HIV Study (WIHS). Submitted
to Conference on Women and HIV/AIDS.
120. Sacks HS, Rose DN, Clark JM, Lau J, Reitman D. Hormone replacement therapy (HRT) as
preventive medicine for post-menopausal women (PMW): a shared decision-making model. Presented at
Society of General Internal Medicine, Boston, MA, May, 2000.
121. Sacks HS, Rose DN, Clark JM, Lau J, Reitman D. Hormone replacement therapy (HRT) as
preventive medicine for breast cancer survivors (BCS): a decision analysis. Presented at Society of
General Internal Medicine, Boston, MA, May, 2000.
23
122. Wilson T, Barron Y, Cohen M, Richardson J, Sacks HS, Greenblatt R. Prevalence and predictors of
adherence to antiretroviral therapy (ART) among HIV+ women. Presented XIII International AIDS
Conference 2000, Durban, South Africa July, 2000.
123. Hessol NA, Preston-Martin S, Seaberg EC, Massad S, Melnick S, Sacks HS, Silver S, Abulafia O,
Levine AM, for the WIHS Collaborative Study Group. Increased incidence of cancer among participants
in the Women's Interagency HIV Study. Presented XIV International AIDS Conference, Barcelona July
2002.
124. Philpott S, Burger H, Anastos K, Ramirez Kitchen C, Salzer E, Robison E, Meyer III WA, Sacks H,
Mathur-Wagh U, Brunner C, and Weiser B. Dynamics of suppression of CXCR4 specific HIV-1 strains
by antiviral therapy. Presented XIV International AIDS Conference, Barcelona July 2002.
125. Ikeda SR, Baban K, Pooran D, Hennig N, Carter G, Indyk DS, Sacks H. Assessment and review of
HIV positive patient medical records from a traditional Siddha medicine hospital in Tamil Nadu, India.
Presented American Public Health Association. 133rd Annual Meeting & Exposition, Dec. 2005.
Philadelphia, PA. Abstract # 107959.
126. Rovetto AL, Lai CY, Sacks HS. Cost-effectiveness of probiotics in preventing hospital-acquired
Clostridium difficile-associated diarrhea. Presented at Interscience Confererence on Antimicrobials and
Chemotherapy, Washington, DC. Dec. 2005. (Session 127, Paper K-1272)
127. Pooran D, Baban K, Ikeda S, Carter G, Indyk D, Hennig N, Sacks H. Linking traditional healing
and evidence-based medicine in the treatment of HIV/AIDS: A needs assessment study of a Siddha
Medicine Clinic in Tamil Nadu, South India. Presented at the 16th Annual International Aids Conference.
Toronto, Canada August 2006. Abstract no. MOPE0804.
128. Jones S, de Gijsel D, Wallach F, Gurtman A, Mensa F, Sacks H. Utility of quantiferon TB Gold
testing for latent TB infection in HIV-infected individuals. Presented at the 16th Annual International
AIDS Conference. Toronto, Canada August 2006. Abstract no. MOPE0113
129. Sacks, H. Design and integration of traditional Chinese medicine (SV) into clinical trials for lung
cancer. Presented at International Forum of Lung Cancer: Fostering Collaboration of Western Medicine
and Traditional Chinese Medicine, Taipei, Taiwan, Nov. 2006. (invited presentation).
130. Sacks H, Wang L-H, Fasy T, Sun L, Sun A. Challenges in developing and conducting clinical trials
of traditional Chinese medicine (TCM) for lung cancer. Presented at Society for Integrative Oncology,
San Francisco, CA, Oct. 2007.
131. Sacks H .Clinical Trials of Traditional Chinese Medicine for Non-small-cell lung cancer. Presented
at Cancer Researchers and CAM Practitioners: Fostering Collaborations; Advancing the Science,
Bethesda, MD, Oct 2007 (invited presentation).
132. Aguilar A, Szyld E, Lezcano J, Barleta A, Indyk D, Sacks H. Evaluation of a voluntary HIV rapid
testing program offered to pregnant women at delivery with unknown HIV status. Presented at Pediatric
Academic Societies Annual Meeting. Honolulu, Hawaii May 2008.
133. F. J. Mensa, S. Jones, A. C. Gurtman, F. Wallach, S. Ruvinsky, R. Bologna, E. Warley, C. Ortiz, R.
Hansen, J. Wisnivesky, P. Cahn, H. Sacks. Usefulness of an Interferon-γ Release Assay in Comparison
with Tuberculin Skin Test (TST) for Latent Tuberculosis Infection (LTBI) in HIV Infected Patients.
Presentation Number: H-237. Presented 49th ICAAC, San Francisco, CA, Sept. 2009.
134. Andreae MH, Carter G, Johnson M, Sacks H. Bayesian methods improve evidence synthesis for
complementary and alternative medicine: Cannabis for painful HIV-related distal sensory polyneuropathy
(HIV-DSPN). Abstracts of the 30th Annual European Society of Regional Anaesthesia (ESRA) Congress
24
2011. Reg Anesth Pain Med. 2011 Sep-Oct;36(5):E101, September/October 2011. Third prize for best
poster
135. Andreae M, Indyk D, Carter G, Johnson M, Suslov K, Sacks H. Lack of Guidelines for Use of
Medical Marijuana for HIV Neuropathic Pain. American Public Health Association (APHA), 140th
Annual Meeting, San Francisco, 27-31, Oct 2012. [Oral presentation]
136. Andreae MH, Carter G, Suslov K, Indyk D, Sacks H and Johnson M. Smoked Cannabis for
neuropathic pain. A novel Bayesian model to impute missing data for responder meta-analysis. The 14th
World Congress on Pain (IASP), Milano, Italy, 27-31 August 2012. Abstract no.PF050.
137. Carter G, Suslov K, Johnson M, Andreae M, Sacks H. Multiple micronutrients in HIV disease: a
Bayesian meta-analysis.19th International AIDS Conference, Washington, DC, 22-29 July 2012 Abstract
no. THPE053
Book Chapters
1. Chalmers TC, Sacks HS. "Prognosis in the cirrhotic with gastrointestinal hemorrhage." In
Gastrointestinal Hemorrhage. Richard G. Fiddian-Green and Jeremiah G. Turcotte, (eds.), Grune and
Stratton, New York, 1980.P.23.
2. Chalmers TC, Sacks HS, Schroeder BJ. "Bleeding from esophageal varices: critique of methods and
timing." In Gastrointestinal Hemorrhage. Dykes, P.W. and Keighley, M.R.B., (eds.), Wright, P.S.G.,
Bristol, England, 1981. pp. 448-454.
3. Sacks HS, Kupfer S, Chalmers TC, et al. "Are uncontrolled clinical studies ever justified?" In
Medical Ethics Abrams, N. and Buckner, M.D. (eds.), MIT Press. Cambridge, MA, 1983. pp. 505-506.
4. Sacks HS, Chalmers TC. "Critical decision making in obtaining laboratory data." In Ambulatory
Care. B. Stimmel, (ed.), Raven Press, New York, 1984. pp. 6-13.
5. Wallace JI, Beatrice S, Bekesi JG, Hannon J, Mann J, Mass L, Sacks HS, et al. "The risk of HIV
infection in former intravenous drug-abusers women." In AIDS in Children, Adolescents and
Heterosexual Adults. Raymond F. Schinazi and Andre J. Nahmias (eds.), Elsevier Science Publishing
Co., Inc. New York, NY 1988. pp. 202-206.
6. Govindarajan S, Edwards VM, Stuart ML, Operskalski EA, Mosley JW, Sacks HS, Transfusion
Safety Group. "Influence of human immunodeficiency virus infection on expression of chronic hepatitis
B and D virus infections." In Viral Hepatitis and Liver Disease. Zuckerman AJ (ed). Alan R Liss, Inc.,
New York, 1988. pp201-204.
7. Goldstein P, Sacks HS, Chalmers TC. "Hormone administration for the maintenance of pregnancy."
In Effective Care in Pregnancy and Childbirth. Murray W. Enkin, Marc J.N.C. Keirse and Chalmers TC.
(eds.), Oxford University Press, Oxford, England (1989). pp 612-623.
8. Sacks HS, Berrier J, Reitman D, Pagano D, Chalmers TC. "Meta-analyses of randomized control
trials: An update of the quality and methodology." In Medical Uses of Statistics. Bailar III JC, Mosteller
F, (eds). NEJM Books, Boston, MA, 1992. pp.427-442.
9. Rhodes R, Baumrin SB, Blaser MJ, Earle WJ, Indyk D, Jabs EW, Moros DA, Richardson LD, Sacks
HS. “Public Health and Research on Populations.” In The Human Microbiome: Ethical, Legal and Social
Concerns. Rhodes R, Gligorov N and Schwab AP, (Eds). Oxford University Press, Oxford, UK, 2013. Pp
208-245.
25
Book Reviews
1. Sacks HS. Review of Readings in Medical Artificial Intelligence: the First Decade, edited by W.J.
Clancy and E.H. Shortliffe. JAMA 1985;253:3011-3012.
2. Sacks HS. Review of Clinical Epidemiology: The Architecture of Clinical Research. By A.R.
Feinstein. N Engl J Med 1986:315:1619.
3. Gottsegen A. and Sacks HS. Review of Health and Numbers: Basic Biomathematical Methods. By
Chap T. Le and James R. Boen. Mount Sinai J Med 1995;62:248.
Letters to the Editor
1. Chalmers TC, Sacks HS. Randomized clinical trials in surgery. N Engl J Med l979;301:1182.
2. Sacks HS, Kupfer S, Chalmers TC. Are uncontrolled clinical studies ever justified? N Engl J Med
1980;303:1067.
3. Cohen ML, Sacks HS, Smith H, Chalmers TC. In-hospital exercise after myocardial infarction. N
Engl J Med 1981;305:1592-3.
4. Sacks HS, Chalmers TC. Lidocaine prophylaxis and myocardial infarction. JAMA 1982;247:2662.
5. Chalmers TC, Sacks HS. Vitamin supplements to prevent neural tube defects. Lancet 1982;1748.
6. Sacks HS, Chalmers TC. Randomized vs historical control trials (reply).
1983;143:2342.
Arch Int Med
7. Messer J, Reitman D, Sacks HS, Smith H, Chalmers TC. Adrenocorticosteroid therapy and peptic
ulcer disease (reply). N Engl J Med 1984; 310:201-2.
8. Caroscio JR, Cohen JA, Yahr MD, Kochwa S, Sacks HS. Quantitative CSF IgG measurements
(reply). Arch Neurol 1984;41:473.
9. Chalmers TC, Sacks HS, Smith J Jr. Bias in Treatment assignment in controlled clinical trials (reply).
N Engl J Med 1984;370:1611-1612.
10. Rosen MJ, Sacks HS, Monitoring oxygenation (reply). Chest 1987; 91:932.
11. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-Analysis. N Engl J Med
1987;317:575.
12. Sze PC, Reitman D, Pincus MM, Sacks HS, Chalmers TC. Antiplatelet agents in stroke prevention.
Stroke 1988;19:436-42.
13. Cheung TW, Sacks HS. The costs of HIV infections. JAMA 1990;263:1067.
14. Ioannidis JPA, Lau J, Sacks HS. Zidovudine in patients with HIV infection (reply) Ann.Int Med.
1996;124:372-3.
15. Sacks HS. The botulism hazard. Ann Intern Med 1997;126:918-919.
16. Sacks HS. Observational studies and randomized trials. N Engl J Med 2000;343:1195
26
17. Crowley LE, Herbert R, Moline JM, Wallenstein S, Shukla G, Schechter C, Skloot GS, Udasin I, Luft
BJ, Harrison D, Shapiro M, Wong K, Sacks HS, Teirstein AS, Landrigan PJ. Response to Dr. Reich's
letter: "'Sarcoid-like' granulomatous pulmonary disease in world trade center disaster responders:
influence of incidence computation methodology in inferring airborne dust causation": "Sarcoid-like"
granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med. 2011
Nov;54(11):894-5. doi: 10.1002/ajim.20995. PubMed PMID: 22006593.
27